Latest Breaking News On - John quisel - Page 1 : comparemela.com

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

John-quisel
Gayle-ross
Guowen-liu
Naseema-gangat
Amy-dickey
Christina-tartaglia
Disc-medicine-inc
Nasdaq
European-hematology-association
Verge-scientific-communications
Exchange-commission

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-states
American
John-quisel
Christina-tartaglia
Verge-scientific-communications
Exchange-commission
Nasdaq
Disc-medicine-inc
Development-expenses
American-society-of-hematology-annual-meeting
Chief-executive-officer
Business-highlights

Sun blind: Disc Medicine's phase II data throw shade on bitopertin

Sun blind: Disc Medicine's phase II data throw shade on bitopertin
bioworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bioworld.com Daily Mail and Mail on Sunday newspapers.

John-quisel
Disc-medicine-inc
Disc-medicine

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light.

Christina-tartaglia
John-quisel
Nasdaq
Disc-medicine-inc
Verge-scientific-communications
Exchange-commission
Patient-global-impression
Chief-executive
Erythropoietic-protoporphyria
X-linked-protoporphyria
Private-securities-litigation-reform-act
Annual-report

Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria

Topline results from AURORA indicate that while bitopertin significantly reduced PPIX levels, improvements in light tolerance were not statistically significant.

Matt-brown-unsplash
John-quisel
Drug-administration
Disc-medicine-inc
Patient-global-impression
Disc-medicine